Emedastinum

Emedastinum Uses, Dosage, Side Effects, Food Interaction and all others data.

Emedastinum is an antihistamine used in eye drops to treat allergic conjunctivitis.

Emedastinum is a relatively selective H1-receptor antagonist.

Emedastinum
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Emedastinum
Generic	Emedastine
Emedastine Other Names	Emedastina, Emedastine, Emedastinum
Type
Formula	C₁₇H₂₆N₄O
Weight	Average: 302.4145 Monoisotopic: 302.210661474
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Emedastinum is a selective H1-receptor antagonist used topically to manage symptoms of allergic conjunctivitis.

For the temporary relief of the signs and symptoms of allergic conjunctivitis.

Emedastinum is also used to associated treatment for these conditions: Seasonal Allergic Conjunctivitis

How Emedastinum works

Emedastinum is a relatively selective, histamine H₁ antagonist. In vitro examinations of emedastine's affinity for histamine receptors demonstrate relative selectivity for the H₁ histamine receptor. In vivo studies have shown concentration-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Emedastinum appears exert negligible effects on adrenergic, dopaminergic and serotonin receptors.

Toxicity

Somnolence and malaise have been reported following daily oral administration.

Food Interaction

No interactions found.

Elimination Route

Ophthalmic use of emedastine usually does not produce measurable plasma concentrations.

Half Life

The elimination half-life in the plasma is 3-4 hours following oral administration.

Elimination Route

Following oral administration, approximately 44% of the total dose can be recovered in the urine over the 24-hour period, with only 3.6% of the dose excreted as unchanged form. Two primary metabolites, 5- and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms.